Phaseline

Companies › Priovant Therapeutics

Priovant Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology, Ophthalmology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brepocitinib
JAK1 inhibitor
JAK1Phase 3Uveitis, Posterior; Lichen Planopilaris; Cutaneous SarcoidosisFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06431373BrepocitinibPhase 3Uveitis, PosteriorOphthalmologyFeb 2028
NCT07532603BrepocitinibPhase 2Lichen PlanopilarisImmunologyDec 2028
NCT06978725BrepocitinibPhase 2Cutaneous SarcoidosisImmunologyDec 2028

Targets

JAK1 (1)

Companies with the same targets

Incyte Pfizer AbbVie Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Dizal Pharmaceuticals Alfasigma Takeda Chengdu Zenitar Biomedical Technology Eli Lilly

Companies built like this

Sun Pharma Japan Alfasigma Triple Hair ReGenTree Laboratorios Sophia S.A de C.V.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.